Viatris Names A Trio Of Complex Injectable Targets Amid Teva Symbicort Interest

Potential For Several Launches In 2025; Key FDA Meeting For GA Depot Before Year-End

 
• By Dean Rudge

Viatris provided several updates for its launch plans in 2025 during the company’s third-quarter earnings call.

business arrow target direction concept to success. Finance growth vector
• Source: Shutterstock

More from Earnings

More from Generics Bulletin